Format

Send to

Choose Destination
J Pediatr. 1999 Mar;134(3):349-51.

Etidronate therapy for hypercalcemia in subcutaneous fat necrosis of the newborn.

Author information

1
Section of Pediatric Endocrinology, Department of Pediatrics, Yale University Medical School, New Haven, Connecticut 06520, USA.

Abstract

Subcutaneous fat necrosis of the newborn (SCFN) is characterized by indurated violet skin nodules and, occasionally, life-threatening hypercalcemia. Current treatments of patients with SCFN-related hypercalcemia are often only partially successful and may be associated with prolonged hypercalcemia. We now report the use of etidronate, a bisphosphonate, to control hypercalcemia in an infant with SCFN.

PMID:
10064674
DOI:
10.1016/s0022-3476(99)70462-2
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center